The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 73 of the 74 references it cites were found in a registry or an index.
Abstract
Significance: IL-1β is an immunomodulatory cytokine that is overexpressed in the brains of patients with Alzheimer’s disease (AD). The NLRP3 inflammasome is an intracellular complex that activates caspase-1, which processes the IL-1β and IL-18 precursors into active molecules. In this study, we used an APP/PS1 mouse model for AD, which confirms significant cognitive losses that are recovered in NLRP3-deficient mice, to evaluate the therapeutic potential of an orally bioavailable and safe NLRP3 inhibitor, OLT1177. OLT1177 ameliorated the phenotype in APP/PS1 mice, as evidenced by rescued spatial learning and memory in the Morris water maze test. Microglia were less activated, cortical plaques reduced, and plasma AD metabolic markers were normalized. OLT1177 is a potential therapeutic option for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig. 4. The administration of oral OLT1177 in APP/PS1 animals for 3 mo significantly reduces microglia activation. (A–C) Evaluation of microglial cells by immunostaining of IBA-1 (IBA-1 in red, DAPI in blue) showed no significant differences in activation status of microglial cells between APP/PS1 animals treated with OLT1177 or without (n = 6 to 9, B; n = 12 to 18, C). (Scale bar in A, 100 µm.) (D and E) In addition the percentage of CD68 expressing cells, as an activation marker for microglial cells, was enhanced in CD11b+/CD45low gated cells of APP/PS1 mice treated with control food (WT vs. APP/PS1 P = 0.015, n = 4 to 5 animals). (F–H) Elevation of proinflammatory cytokines IL-1β, IL-6, and TNF-α was detected in brain homogenates of APP/PS1 mice (WT vs. APP/PS1 P = 0.019, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.001, F; WT vs. APP/PS1 P = 0.039, APP/PS1 vs. APP/PS1 7.5 g/kg P = 0.01, G; APP/PS1 vs. APP/PS1 7.5 g/kg OLT1177 P = 0.011, H; n = 6 to 12 samples). (I) The amount of Aβ plaques was determined using immunostaining for IBA-1 and BAM-10 (clone for Aβ) (IBA-1 in green, DAPI in blue, BAM-10 in red). (Scale bar in I, 500 µm.) (J) Plaque load was lower in the cortex of the APP/PS1 animals fed with 7.5 g/kg OLT1177 compared to APP/PS1 animals (cortex [CX] P = 0.03; hippocampus [HC] P = 0.16, n = 6 in both groups). Data are presented as mean ± SEM. *P < 0.05 compared to WT, +P < 0.05, +++P < 0.001 compared to APP/PS1 CTRL.](https://figures.cochat.ai/paper-figures/6122e4acafc94eb79811544a2ca9b8a3/the-nlrp3-inflammasome-inhibitor-olt1177-rescues-cognitive-impairment-in-a-mouse-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in another study, the inhibition of NLRP3 by OLT1177 significantly improved cognitive impairment in a mouse model of Alzheimer’s disease [84].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Developments of a water-maze procedure for studying spatial learning in the rat
Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 4×
“Heneka et al. (16) pointed out the important role of the NLRP3 inflammasome/caspase-1 axis in AD pathogenesis by demonstrating significant improvements (e.g., in cognition) in APP/PS1 mice (a mouse model for AD) when crossed with NLRP3 − / − animals.”
InfluentialThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
(2015) · HAL · Cited by 2,238
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Innate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“145 These results suggest that microglia respond to the pathology of AD.”
MethodInfluentialNLRP3 and pyroptosis blockers for treating inflammatory diseases
Coll, R. C., Schroder, K., & Pelegrín, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.003 · Cited by 755
Blevins, H. M., Xu, Y., Biby, S., & Zhang, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879021 · Cited by 587
Cai, Y., Liu, J., Wang, B., Sun, M., & Yang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856376 · Cited by 351
“Dapansutrile (OLT1177), an orally available small molecule inhibitor for NLRP3 inflammasome which can silence caspase1 and IL-1b and has well tolerated and free side effects in humans, could rescue synaptic plasticity, suppress inimical microglia, and reduce the number of plaques in APP/PS1 mouse model for AD (59).”
BackgroundTargeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Metadata
- Authors
- Lonnemann, N., Hosseini, S., Marchetti, C., Skouras, D. B., Stefanoni, D., D’Alessandro, A., Dinarello, C. A., & Korte, M.
- Affiliations
- Technische Universität Braunschweig (DE)
- Helmholtz Centre for Infection Research (DE)
- University of Colorado Anschutz (US)
- Olatec (United States) (US)
- University of Colorado Denver (US)
- Radboud University Nijmegen (NL)
- Department of Cellular Neurobiology, Zoological Institute, Technische Universität Braunschweig, 38106 Braunschweig, Germany;
- Corresponding author
- Dinarello, Charles A.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2020-11-30
- Volume
- 117
- Issue
- 50
- Pages
- 32145-32154
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC7749353
- OpenAlex
- W3108308610
- Cited by
- 298
- References
- 74
- Citations by year
- 2026: 51 · 2025: 53 · 2024: 50 · 2023: 56 · 2022: 55 · 2021: 33
- FWCI
- 21.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion, cc-by-nc-nd)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (AI15614)
- Deutsche Forschungsgemeinschaft (SFB854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, Alzheimer's disease, cognitive impairment, IL-1β, caspase-1, APP/PS1 mice, microglial activation, amyloid plaques, spatial learning and memory, anti-inflammatory therapy
- MeSH terms
- Behavior Observation Techniques, NLR Family, Pyrin Domain-Containing 3 Protein, Administration, Oral, Alzheimer Disease, Animals, Behavior, Animal, Cerebral Cortex, Disease Models, Animal, Humans, Male, Mice, Transgenic, Neuronal Plasticity, Nitriles, Sulfones, Amyloid beta-Protein Precursor, Microglia, Mice, Presenilin-1, Inflammasomes, Cognitive Dysfunction, Spatial Memory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. https://app.cochat.ai/papers/10.1073/pnas.2009680117
- The paper
- Lonnemann, N., Hosseini, S., Marchetti, C., Skouras, D. B., Stefanoni, D., D’Alessandro, A., Dinarello, C. A., & Korte, M. (2020). The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2009680117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.